In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

July 31, 2026

Vol.52 No.30

Regulatory News

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

In a video captioned “The High-T Department of War” and posted on X, Secretary of Defense Pete Hegseth announced that he was authorizing a screening program for troops to ensure “you have the right testosterone levels to operate at your absolute best.”

July 24, 2026

Vol.52 No.29

By Claire Marie Porter

Clinical Roundup

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

A study, which focused on the DNA switches of prostate cancer cells, reveals insights into enhancers that become active during cancer development and turn on genes linked to the disease. The study found that enhancers work cooperatively in 3D networks, rather than as isolated switches. Some enhancers function as “central hubs” that control many genes, while others play a supporting role. These findings could help with the development of targeted cancer therapies.

July 24, 2026

Vol.52 No.29

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

YOU MAY BE INTERESTED IN

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

FDA approves Pluvicto for mHSPC

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

Renew today!

Subscriber content

Never miss an issue!

Login

In phase II studies Apatorsen improved outcomes in bladder, prostate cancers

YOU MAY BE INTERESTED IN

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

FDA approves Pluvicto for mHSPC

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment”

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

Never miss an issue!

Login

Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warnings
Experts caution the move amounts to a “huge, unregulated, natural experiment”